Moreover, treatment with guadecitabine or DAC vs. AZA up-regulated (FC ≥2) the mRNA expression of NY-ESO-1 in 100% (2/2) and 100% (2/2) vs. 50% (1/2); of MAGE-A3 in 8.3% (1/12) and 16.7% (2/12) vs. 8.3% (1/12) and of MAGE-A1 in 27.3% (3/11) and 54.5% (6/11) vs. 36.3% (4/11) in CTA-positive melanoma cell lines (Supplementary Tables 3–5). Here, MAGEA3 is linked to melanoma.